Home / Resources / Articles / Three Subtypes, One Diagnosis: Scientists Uncover Hidden Differences in Adult Type 1 Diabetes

Three Subtypes, One Diagnosis: Scientists Uncover Hidden Differences in Adult Type 1 Diabetes

Nov 14, 2026
2,058 views
 

Two adults can receive the same type 1 diabetes diagnosis yet have very different needs. Why does one still produce measurable insulin while another has almost none? A new prospective study identified three distinct subtypes of type 1 diabetes in adults, offering new clues about why the disease varies from person to person. Published October 30, 2026, in The Lancet Diabetes & Endocrinology, the research highlights important differences in autoimmune activity, insulin sensitivity, and remaining insulin production. Moreover, these findings could help guide future research into personalized diabetes care.

Table of Contents

  • How researchers identified three diabetes profiles
  • Three distinct subtypes of type 1 diabetes in adults
  • Why disease progression and complication risks differ
  • What the findings mean for clinical care

How Researchers Identified Three Adult Type 1 Diabetes Profiles

Researchers analyzed 600 adults aged 18 to 69 who participated in the German Diabetes Study. Participants had received a type 1 diabetes diagnosis within the previous year or had tested positive for GAD antibodies after initially being diagnosed with type 2 diabetes. The researchers followed participants for an average of 6.1 years.

 

Instead of grouping patients by age or body weight alone, the team used machine learning to identify patterns across five clinical measurements. These included GAD antibody status, fasting C-peptide, glucose, triglycerides, and HDL cholesterol.

C-peptide is particularly useful because it helps estimate how much insulin the pancreas continues to produce. Meanwhile, GAD antibodies provide evidence of an autoimmune response associated with type 1 diabetes.

Researchers also examined genetic risk, insulin sensitivity, beta-cell function, and diabetes-related complications.

Importantly, the investigators tested their findings in an independent group of 483 adults from the German Diabetes Prospective Follow-up Registry. They observed a similar pattern of three clinical and metabolic groups.

This replication strengthens confidence in the findings. However, the results do not yet establish that patients should receive different treatments based on their assigned subtype.

The complete prospective cohort study provides additional details about the researchers' methods and findings.

Three Distinct Subtypes of Type 1 Diabetes in Adults

The researchers identified three groups with different clinical and metabolic characteristics. Although all participants were being studied in the context of adult type 1 diabetes, their disease profiles were not identical.

The first group, described as classic type 1 diabetes, was positive for GAD antibodies. These patients generally had a lower body mass index, greater insulin sensitivity, and more severe loss of beta-cell function.

In practical terms, their bodies responded relatively well to insulin, but their pancreases produced less of it.

The second group, called mixed type 1 diabetes, was also GAD-antibody positive. However, patients typically had a higher body mass index, greater insulin resistance, and better-preserved beta-cell function.

This combination is especially interesting because insulin resistance is commonly associated with type 2 diabetes. Nevertheless, patients in the mixed group still showed evidence of autoimmune diabetes.

Notably, the classic and mixed groups had similar autoimmune characteristics and genetic risk scores for type 1 diabetes. Therefore, their metabolic differences did not necessarily reflect different levels of autoimmune risk.

The third group was GAD-antibody negative and had a lower overall genetic risk score for type 1 diabetes.

However, the researchers did not identify clear differences in certain high-risk HLA genetic patterns across the groups.

These findings reinforce an important clinical lesson: a negative GAD antibody test does not automatically exclude type 1 diabetes. Additional antibody testing, C-peptide measurement, and careful assessment of the patient's clinical history may help clarify an uncertain diagnosis.

Why Disease Progression and Complication Risks Differ

One of the study's most notable findings involved the timing of beta-cell decline.

Researchers estimated that the mixed subtype was positioned approximately 6.1 years earlier along a modeled trajectory of declining beta-cell function than the classic subtype.

This does not mean that patients in the mixed group lived six additional years without significant disease or that treatment delayed progression.

Instead, the results suggest that insulin resistance may cause blood glucose levels to rise enough for diabetes to become clinically apparent while the pancreas still produces a meaningful amount of insulin.

Consequently, two adults diagnosed at approximately the same time may have very different levels of remaining beta-cell function.

The study also identified differences in diabetes-related complications.

Compared with the classic group, patients in the mixed group had a higher adjusted hazard of diabetic retinopathy, with a hazard ratio of 4.93. However, the confidence interval was wide, ranging from 1.71 to 14.24, indicating uncertainty about the size of this association.

Researchers also observed differences in hypoglycemia risk and cardiovascular autonomic neuropathy across the three groups.

These findings suggest that preserved insulin production does not necessarily indicate a lower risk of every diabetes complication.

However, the observational study cannot establish that membership in a particular subtype directly causes these outcomes.

Further research is needed to determine whether the groups can reliably predict long-term complications beyond established clinical risk factors.

What the New Diabetes Subtypes Mean for Care

For now, these newly identified groups should not replace established diagnostic criteria or guide treatment decisions.

The updated 2026 American Diabetes Association and European Association for the Study of Diabetes consensus report emphasizes individualized care for adults with type 1 diabetes.

Importantly, clinicians should avoid assuming that an adult with excess body weight or insulin resistance must have type 2 diabetes.

Autoimmune diabetes can develop in adults with a wide range of body sizes and metabolic characteristics. Likewise, some patients may retain measurable insulin production long after their initial diagnosis.

These overlapping characteristics can make diagnosis challenging.

For example, latent autoimmune diabetes in adults (LADA) may initially resemble type 2 diabetes because insulin production can decline gradually.

Therefore, clinicians may need to consider antibody testing, C-peptide results, and the patient's response to treatment when the diabetes type remains uncertain.

Once the diagnosis is established, individual insulin requirements, glucose monitoring data, and cardiovascular risk factors remain central to management.

Regular screening for complications is equally important. Recent research on type 1 diabetes foot screening also highlights the growing interest in matching preventive care to individual risk.

Meanwhile, these newly identified diabetes profiles could create opportunities for future treatment research.

Scientists may eventually investigate whether certain patients respond differently to therapies designed to preserve beta-cell function or modify autoimmune disease activity.

For example, immune therapies such as teplizumab (Tzield) have created interest in delaying the progression of early-stage type 1 diabetes. However, this cohort study did not evaluate teplizumab or establish whether any of the three groups would benefit from a particular disease-modifying therapy.

Before subtype-based treatments become part of routine care, researchers must demonstrate that using this classification improves meaningful clinical outcomes.

Patients who have questions about their diagnosis or treatment should consult a qualified healthcare professional for individualized guidance.

Ultimately, the findings offer a promising research framework rather than an immediate change to clinical practice.

Conclusion

The three newly identified groups highlight important differences among adults who share a type 1 diabetes diagnosis.

In particular, autoimmune markers, insulin resistance, and remaining insulin production may influence how the disease first becomes apparent.

Although complication patterns also differed, larger and more diverse studies are needed to confirm the clinical value of these findings.

For now, accurate diagnosis, individualized insulin management, and regular complication monitoring remain essential.

As researchers learn more about these distinct clinical profiles, the findings may eventually support more targeted risk assessment and treatment strategies.

Frequently Asked Questions

  1. What are the three newly identified subtypes of adult type 1 diabetes?
    The study identified classic GAD-positive type 1 diabetes, mixed GAD-positive type 1 diabetes, and a GAD-negative group with a lower overall genetic risk score for type 1 diabetes. Each group showed different metabolic characteristics.
  2. How does the mixed subtype differ from classic type 1 diabetes?
    Patients in the mixed group generally had greater insulin resistance, higher body mass index, and better-preserved beta-cell function. However, both groups showed evidence of autoimmunity and similar genetic risk scores for type 1 diabetes.
  3. Does a negative GAD antibody test rule out type 1 diabetes?
    No. Some people with type 1 diabetes test negative for GAD antibodies. Additional tests, including other islet autoantibodies and C-peptide measurements, may help clarify the diagnosis.
  4. Do these subtypes affect the risk of diabetes complications?
    The study found differences in retinopathy, hypoglycemia, and cardiovascular autonomic neuropathy across the groups. However, additional research is necessary to determine whether the classification reliably predicts individual complication risks.
  5. Can doctors use these diabetes subtypes to choose treatments today?
    Not yet. The findings provide a foundation for future personalized medicine research, but there is currently insufficient evidence to recommend subtype-specific treatment strategies.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.